"One week Jun" "defamation of Chinese medicine will be punished" is pure "misreading"; Vaccine Summit Raises...

Guide: This week,""traditional Chinese medicine" on the hot search, a number of pharmaceutical executives have left!
this week's point of view:
"defamation of Chinese medicine will be punished" is pure "misreading";
central set the tone to revitalize Chinese medicine, ushering in great benefits;
vaccine summit to raise $8.8 billion to help vaccine research and development;
Kantai biological controller shone 23.554 billion dollars overnight;
government news
good opportunity! Central set tone to revitalize Chinese medicine, usherin in the great good!On June 2,
, a symposium of experts and scholars hosted by Xi Jinping proceeded smoothly at the Great Hall of the People in Beijing, aiming to summarize the experience of prevention and control of the new coronary pneumonia epidemic in stages, and to make exchange suggestions on improving the institutional mechanism for the prevention and control of major outbreaks in China, improving the national public health system, improving the level of medical treatment, playing the role of Traditional Chinese Medicine, strengthening scientific and technological support, and improving the system of public health laws and regulations.During the
experts said that the development and research of new Chinese medicine is a huge system engineering, need a number of professional, departmental overall collaboration, the mutual penetration and integration of many disciplines, in maintaining and carrying forward the characteristics and advantages of Chinese medicine at the same time, learn from modern scientific concepts, the use of modern science and technology and methods, highlighting clinical value and advantages, such new drugs in line with the requirements of social life development.
Xi pointed out that the combination of Chinese and Western medicine, the use of Chinese and Western medicine, is a major feature of the epidemic prevention and control, but also the essence of traditional Chinese medicine heritage, the vivid practice of keeping the positive innovation. We should strengthen the combing and excavation of the essence of classical medicine, build a number of scientific research support platforms, reform and improve the review and approval mechanism of Chinese medicine, and promote the research and development of new Chinese medicine and industry. We should strengthen the construction of the service system of Chinese medicine and improve the emergency and treatment capacity of Chinese hospitals. We should strengthen the construction of chinese medicine characteristics and build a high-level national team for the prevention and control of Chinese medicine disease. We should strengthen the organizational leadership of the work of Chinese medicine and promote the mutual complement and coordinated development of Chinese and Western medicine.
this symposium of experts and scholars, in the clear "combination of Chinese and Western medicine, Chinese and Western medicine and use" the overall idea at the same time, further emphasize to strengthen the essence of classical medicine combing and mining, heritage essence, keep the right innovation.
9 major measures to encourage the development of Chinese medicine?On May 29,
, the Beijing Health and Health Commission issued a "public consultation on the Regulations on Chinese Medicine in Beijing (Draft for Public Comments). Public consultation from 29 May to 28 June 2020.
"draft of opinion" published a number of Chinese medicine incentives, compared with the past, this time more support, more specific and clear provisions.
specific measures as follows:
to raise the salary level of chinese medicine service personnel at the grass-roots level,
to strengthen the training of Chinese medicine,
village doctors can self-seed Chinese medicine,
to combat Chinese medicine black,
non-Chinese medicine category physicians can prescribe traditional Chinese medicine;
medical institutions without obtaining preparation approval number,
Chinese medicine services into the public health service system;
to increase the support for medical insurance for Chinese medicine;
young doctors to participate in teacher education, give priority to evaluation of the first;
the official response: "defamation of Chinese medicine will be sentenced" is purely "misreading"
in response to the recent Beijing Health and Care Commission issued the "Beijing Public Draft of The Draft" mentioned in the "Beijing Chinese Medicine Regulations "Content, triggered a wide range of discussions in the community, the vast majority of netizens and industry people expressed disapproval, and said whether it means that can not oppose, question Chinese medicine, doubters will be punished."
the relevant person in charge of the Beijing Municipal Administration of Traditional Chinese Medicine responded: Netizens misread the draft, not that the vilification was imposed. The draft is still in the process of seeking comments and will eventually be comprehensively assessed in the light of feedback recommendations, without excluding the possibility of amending or deleting some of the provisions. The definitive version, which was finally considered by the Standing Committee of the Municipal People's Congress, is expected to be released in September.
the State Health Insurance Administration proposed to build a credit rating, pharmaceutical enterprises commercial bribery and other acts will be included in the blacklist
June 5, the State Health Insurance Administration issued two documents "pharmaceutical prices and credit evaluation of the operational norms (draft for comments)" and "on the establishment of pharmaceutical prices and recruitment credit evaluation system guidance (second draft for comments)", to establish a list of pharmaceutical prices and recruitment of credit matters, pharmaceutical commercial bribery enterprises, abuse of market dominance, market price manipulation and other acts will be included in the six kinds of "black list."
requirements, the development of the credit rating of pharmaceutical enterprises, according to the nature of the breach of trust, circumstances, time limit, and the scope of influence and other factors, the pharmaceutical enterprises in the local tender procurement market to assess the breach of trust as general, medium, serious, especially serious four levels, dynamic updates on a quarterly basis.At the same time, the
, the object of governance from doctor-oriented to enterprise responsibility, the establishment of pharmaceutical enterprises credit automatic repair and active repair mechanism, to encourage pharmaceutical enterprises to repair credit. If the medical enterprise's breach of trust behavior exceeds a certain period of time, it will no longer be retroactively included in the scope of credit evaluation and will realize automatic repair.
the National Health Insurance Administration: The national supplies code nearthe
June 4, the National Health Insurance Administration issued "on the publicity of medical medical supplies classification and code database of the second batch of medical supplies information notice", the content of the "National Medical Security Administration on the issuance of medical security standardization of the work of the relevant requirements, the second batch of medical supplies information will be published."
the National Health Insurance Administration pointed out that the trend is to accelerate the promotion of unified medical insurance information business coding standards, the formation of a national "common language."
after the public no objection, the second batch of medical supplies information will be included in the national medical supplies classification and code database for use by the various medical security departments.
pointed out: by 2020, on the basis of the construction of a unified national medical insurance information system, and gradually realize the diagnosis of diseases and surgical operations, such as 15 information business coding standards. Consistency evaluation is equivalent to the establishment of supplies for the "quality standard line", the standard line above the product negotiation procurement, even if only low price is to take, quality can also have the most basic guarantee.
in addition to this, compared with the consistency of the drug evaluation process, perhaps supplies will also face a wave of a big reshuffle. Many small businesses in the supply space have only one or two products and their income is not high.
Vaccine Summit raised $8.8 billion to help vaccine research and development, Li Keqiang video conference speech
June 4 vaccine summit video conference ended, the summit called on governments and international organizations to work together to raise funds to support vaccination, jointly fight disease and save lives. More than 30 leaders, as well as the United Nations, the World Health Organization and other international organizations attended the video summit,
Li Keqiang at the meeting, pointed out that in the outbreak is not over, the challenge is still serious, vaccines are a strong shield against the virus. China is stepping up scientific research on new crown vaccines, drugs and testing reagents, and attaches great importance to international cooperation in vaccine research and development.
more than 6.59 million cases were confirmed worldwide as of 7:33 p.m. Beijing time on June 5, according to real-time data from Johns Hopkins University in the United States. In response to the dire outbreak, the summit raised $8.8 billion, exceeding the $7.4 billion fundraising target for gavies.
Health and Welling Council issued the "China Eye Health White Paper", the preparation of the "14th Five-Year Plan" National Eye Health Plan
June 5 morning, the National Health and Care Commission held a press conference to introduce the progress and effectiveness of China's eye health work. At the meeting, the National Health and Health Commission issued the "China Eye Health White Paper", clearly the next step will be combined with China's national conditions and blinding eye disease spectrum changes, the preparation of the "14th Five-Year Plan" national eye health plan, further improve the three-level anti-blind and eye health service system, strengthen the construction of the primary ophthalmology professional team, establish the ophthalmology medical quality control system, promote the development of high-quality ophthalmological medical services, and strive to meet people's increasing needs of eye health.
experts called for eye screening to be included in the slow-motion screening system, effectively reducing a large number of human costs. The use of wireless networks to transfer information flow, the flow of patients into information flow, the cost of disease control screening will be greatly reduced. So we also call on the state to take the next step, with economic development to allow, to ensure that the dangerous population once a year of eye-water examination.
the market is hot
blood products unit price rose, the domestic market can replace imports?
it is understood that recently manufacturers took the lead in raising the factory price of human haemoglobin, to 5g / bottle of this specification, the price has been from the original about 310 yuan or 320 yuan / bottle to the current 340 yuan / bottle. The main reason is affected by the outbreak, the first half of this year," domestic pulp production fell, coupled with market expectations of overseas outbreaks affecting human haemoglobin imports.
how can Zhejiang pharmaceutical companies adapt to the new situation of medical insurance fee control in the
of DRGs points?
, Zhejiang Provincial and Hangzhou Municipal Health Insurance Bureau issued the "Zhejiang Provincial and Hangzhou City Basic Medical Insurance Hospitalization Fee DRGs Point Payment Regulations (Trial)" (hereinafter referred to as "Rules"), clear Zhejiang DRGs to achieve the annual total budget system of hospital insurance fund and "balance retention, overspend sharing" responsibility sharing mechanism, and detailed DRG grouping standards, DRG points and differential coefficients, and how to pay.
in addition, the content requirements, fixed-point medical institutions should reasonably control the in-patient self-funded drug, materials and medical treatment project costs, the proportion of expenses outside the scope of individual policies in principle to control within 15%.
now DRGs from the previous 30 cities pilot to today's provincial and municipal level gradually pushed away, not only means that the medical institutions pay reform in-depth, but also the pharmaceutical industry will have a profound impact. Put more means in cooperation with hospitals to improve drug use, management level, "gold sales" was completely abandoned.
Corporate Information
Sanofi: The new crown vaccine will be developed in human clinical trials at the end of the year
June 3, the media confirmed to Sanofi, Sanofi CEO Paul Hudson in an interview with the U.S. Consumer News and Business Channel (CNBC) mentioned that "basically explains our current progress", the new crown vaccine may be conducted in human clinical trials at the end of the year.
Sanofi has five global divisions, of which Sanofi Pasteur is its vaccine division. Sanofi said that since the outbreak of the new crown, Sanofi Pasteur has accelerated the development of a gene recombination vaccine and a new mRNA vaccine for the new coronavirus.
world health organization statistics show that there are currently more than 120 candidate vaccines worldwide. According to Zhong Nanshan on May 30, China currently has five vaccines in the second phase of clinical trials, including The adeno carrier Ad5-nCoV vaccine developed by KangSino and Chen Wei team of the Academy of Military Sciences, as well as four inactivated vaccines.
Kantai Bio: The controlling company lost $23.554 billion in value overnight
on the evening of May 29th, THE GEM listed company Kantai Bio issued a stock change report, due to the dissolution of the marriage relationship and the division of property. Du Weimin, the controlling shareholder and the actual controller, intends to split 161 million of the 344.7 million shares held by the individual into his ex-wife, Yuan Liping, accounting for 23.99 percent of the shares held by the listed company. By the close of the day, Kantai Bio's share price was 146 yuan per share, which means that Du Weimin had to give his ex-wife 23.554 billion yuan, the most expensive "break-up fee" in the history of A-shares.
Started with a vaccine, the company's main products include recombinant hepatitis B vaccine (wine yeast), haemophilus influenzae type b vaccine, measles rubella combined detoxification live vaccine, cellless bacillus b haemophilus vaccine, 23-valent pneumococcal polysaccharide vaccine, etc.
performance, in recent years has continued to grow, Du Weimin's personal value is also rising. Its total operating income rose from 1,161 million yuan to 1,943 million yuan, and its net profit rose from 215 million yuan to 575 million yuan, with the company's growth rate maintaining at a high growth rate of more than 31% for the first consecutive year.
also in the 2019 Hurun Rich List, Du Weimin won 130 with a wealth of 24.5 billion yuan, and in February 2020, Du Weimin ranked 524th on Hurun's global rich list with a fortune of 33 billion yuan.
$23.5 billion in break-up fees, perhaps the couple is split up in divorce, but for investors, the sensitive point of time, coupled with Du Weimin's controversial past, may be paid for by them. Such a move is hardly understood by investors as true love, but will be seen as a red alert, "the share price is inflated", "disguised to reduce", the mood began to surface.
Yunnan White Medicine: distribution accounted for 91.38% of the year's profit
recently Yunnan White Medicine to shareholders per 10 shares of the cash dividend of 30 yuan (including tax), the total cash dividend amounted to 3.832 billion yuan, the dividend program a stone stirred up a thousand waves in the market, causing many doubts in the capital market.
even more amazing is that Yunnan White Medicine's cash dividend payment accounted for 91.38 percent of the year's net profit. Is such a move completely counterintuitive, but rather does not please investors, but raises widespread concern among the "citizens"?
According to the Yunnan White Medicine Annual Report, the growth rate of non-net profit in 2019 was negative for the first time in 20 years, down 21.54 percent year-on-year. The decline was due to a change in the revenue structure, which led to a decline in gross margins, and was also due to a surge in overheads.
in fact, as a typical high-quality white horse stocks, Yunnan white medicine once market position in Guizhou Maotai, but also hold top secret national protection varieties, abnormal behavior, the decline in profit acquisition is the capital market's biggest source of worry.
3 new three-plate pharmaceutical companies to turn to the science and innovation board!
recently, Applications from Jiangsu Kofiping Pharmaceutical Co., Ltd. (hereinafter referred to as Kofiping), Shanghai Jiang Biotech Co., Ltd. (hereinafter referred to as Jiang Bio) and Shanxi Jinbo Biopharmaceutical Co., Ltd. (hereinafter referred to as Jinbo Bio) were accepted.
according to the prospectus disclosed that all three enterprises have chosen the first set of standard listing, that is, "the expected market value is not less than 1 billion yuan, the last two years of net profit is positive and cumulative net profit is not less than 50 million yuan, or the expected market value is not less than 1 billion yuan, the most recent year net profit is positive and operating income is not less than RMB1."